Recent Press Releases

Phase III Study Showed Rituxan® for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in

Rituxan Decreased the Risk of Needing Later Treatment with Chemotherapy or Radiotherapy by 80 Percent SOUTH SAN FRANCISCO, Calif. & WESTON, Mass.--(BUSINESS WIRE)-- Genentech, Inc., a member of

Lundbeck Reports Positive Phase III Study Results for Clobazam in the Adjunctive Treatment of Seizures Associated with Len

Two highest dosages of clobazam as add-on therapy achieved a robust statistically significant reduction in average weekly rate of drop seizures, compared with placebo1 77.6 percent of patients who

IDRI Awarded $790,200 Grant from US Government to Develop Pandemic Flu Vaccine with Cantacuzino Institute

SEATTLE, Dec. 4, 2010 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) today announced it has received a $790,200 grant from the Biomedical Advanced Research and

Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia

NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a

American Imaging Management Adds New Features to Patient Safety Program

CHICAGO, Dec. 3, 2010 /PRNewswire/ -- American Imaging Management, Inc. (AIM), a leading diagnostic imaging benefit management and technology company and operating subsidiary of WellPoint, Inc.

Momenta Pharmaceuticals Sues Teva for Patent Infringement

CAMBRIDGE, Mass., Dec. 2, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today

Sermo Study shows 70% of Specialists are Ready to Replace Warfarin

New Sermo Report Discusses New and Anticipated Anticoagulant TreatmentsCAMBRIDGE, Mass., Dec. 3, 2010 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online community for

Bristol-Myers Squibb Announces the Expiration and Final Results of its Cash Tender Offer

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) announced today the expiration, as of 11:59 p.m., New York City time, on December 2, 2010, of its previously announced cash tender

A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to International Clients

New clients are invited to use the services of a web pharmacy that has been created recently to provide customers with the most popular drugs, like generic Cialis, for the most competitive prices.LAS

Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting

Final Results From The Largest And Longest Study Of Nplate® For The Treatment Of Adult Chronic ITP To Be PresentedTHOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN)

MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers

NOVATO, Calif., Dec. 2, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed

US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer

WILMINGTON, Del., Dec. 2, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss

Teva Comments on Patent Infringement Lawsuit Filed by Momenta and Sandoz

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the patent infringement lawsuit filed by Momenta Pharmaceuticals, Inc. and Sandoz Inc. Teva received

Norton Healthcare Enters Agreement With Microsoft Corp.

Norton Healthcare has entered into an agreement with Microsoft Corp. to use its health solutions platforms to support its Accountable Care Organization (ACO) initiativeLOUISVILLE, Ky. and REDMOND,

Centrum® and Molly Shannon Search for 'America's Most Amazingly Energized Woman' This Holiday Season

Consumers are invited to nominate someone who lives life and love to the fullest during the busiest time of the yearMADISON, N.J., Dec. 2, 2010 /PRNewswire/ -- Getting it all done while enjoying life

Surveyed U.S. Oncologists Indicate That if Iressa and Tomtovok Were Approved for Treating NSCLC Patients With EGFR Mutations, Bo

However, If Iressa and Tomtovok Were Priced at a 20 Percent Premium to Tarceva, These Agents Would Be Excluded From 40 Percent of Surveyed MCOs' Formularies, According to a New Report from Decision

IBM Powers Russian Pharmaceutical Company PROTEK

IBM Powers Russian Pharmaceutical Company PROTEKIBM's POWER7 systems replace HP servers MOSCOW, Nov. 22, 2010 /PRNewswire-FirstCall/ -- IBM (NYSE: IBM) today announced that Russian pharmaceutical

Datex Announces New IT Services for WMS Software Clients

Datex recently announced its newest service offering for clients of its FootPrint WMS software. Datex IT Services will be available to all clients that purchased Datex FootPrint® and that need

Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen

NANJING, China, Nov. 30, 2010 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development,